Empagliflozin vs Tofacitinib

Empagliflozin vs Tofacitinib: Overview

This comparison examines the pharmacological differences between Empagliflozin and Tofacitinib.

Mechanism of Action

Empagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption.

Tofacitinib: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

Pharmacokinetics

Half-life: Empagliflozin — 12.4 hours; Tofacitinib — 3.2 hours.

Chemical Properties

Molecular Formula: Empagliflozin — C23H27ClO7; Tofacitinib — C16H20N6O.

Molecular Weight: Empagliflozin — 450.9100 g/mol; Tofacitinib — 312.3700 g/mol.

Type: Empagliflozin — Small molecule; Tofacitinib — Small molecule.